This updated clinical practice guideline evaluates and provides evidence-based recommendations for the assessment and management of persistent (≥6 months), bothersome tinnitus in adults (≥18 years), covering diagnostic evaluation, specialty referral, and therapeutic interventions.
Strong recommendations include: distinguishing bothersome from non-bothersome tinnitus, screening for self-harm risk, and avoiding routine neuroradiologic imaging. Recommendations support audiological evaluation, hearing aid referral, cochlear implant evaluation when criteria are met, and CBT. Clinicians should not routinely offer antidepressants, anticonvulsants, anxiolytics, intratympanic medications, dietary supplements, or rTMS. Sound enrichment and bimodal neuromodulation are offered as options.
The guideline is based on a publisher page excerpt rather than the full text, so the strength of underlying evidence for each Key Action Statement and the detailed evidence review cannot be fully assessed. The target population is limited to adults, so findings do not apply to pediatric patients. Recommendations against several pharmacologic and neuromodulatory treatments reflect current evidence gaps rather than definitive proof of inefficacy.
For adults with persistent, bothersome tinnitus, prioritize CBT as the most strongly recommended treatment, refer for hearing aid or cochlear implant evaluation when appropriate, and avoid routinely prescribing medications (antidepressants, anticonvulsants, anxiolytics), supplements, or rTMS specifically for tinnitus. Always screen for self-harm risk in this population.
Explore related topics